Pancreatic Adenocarcinoma, Version 2.2017
Pancreatic Adenocarcinoma, Version 2.2017
复制标题
DOI：
10.6004/jnccn.2017.0131
复制
发表时间：
2017-08-01
影响因子：
13.4
通讯作者：
Darlow, Susan
中科院分区：
文献类型：
--
作者：
Tempero, Margaret A.;Malafa, Mokenge P.;Darlow, Susan
导管腺癌及其变体占大多数胰腺恶性肿瘤。高质量的多相成像有助于术前区分符合根治性切除条件的患者和无法切除的患者。全身治疗用于新辅助或辅助胰腺癌治疗，以及局部晚期不可切除和转移性疾病的治疗。临床试验对于胰腺癌治疗取得进展至关重要。NCCN胰腺癌指南重点关注诊断和全身治疗、放射治疗和手术切除治疗。
Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.